cryptotanshinone has been researched along with Parkinson Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Wang, Q | 1 |
| Agarwal, S; Chang, YM; Desai, TD; Ho, TJ; Huang, CY; Ju, DT; Kuo, WW; Liao, SC; Lin, YJ; Sun, JM; Yeh, YL | 1 |
| Baek, A; Jeon, YJ; Kim, J; Lee, JE; Lee, M; Seo, KS; Sim, H; Son, MY; Yoo, HM; Yoon, JS | 1 |
3 other study(ies) available for cryptotanshinone and Parkinson Disease
| Article | Year |
|---|---|
Cryptotanshinone ameliorates MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Humans; Mice; Neuroblastoma; Oxidative Stress; Parkinson Disease; Phenanthrenes; STAT3 Transcription Factor | 2022 |
Cryptotanshinone protects against oxidative stress in the paraquat-induced Parkinson's disease model.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease | 2023 |
Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson's Disease.
Topics: Case-Control Studies; Cell Line; Cellular Reprogramming; Gene Expression Regulation; Humans; Induced Pluripotent Stem Cells; Leupeptins; Mitochondria; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Phenanthrenes | 2020 |